Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novavax Inc (NQ: NVAX )

13.61 +1.69 (+14.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,215,153
Open 11.87
Bid (Size) 13.55 (3)
Ask (Size) 13.65 (1)
Prev. Close 11.92
Today's Range 11.82 - 14.03
52wk Range 3.532 - 23.86
Shares Outstanding 74,484,166
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Should You Buy Novavax Stock After This Regulatory Win?
The biotech continues to earn important wins, but is it enough? 
Via The Motley Fool
Why Are Novavax Shares Trading Lower Today?
Novavax Inc. (NASDAQ: NVAX) shares are trading lower Thursday following multiple significant announcements. Here's what you need to know. 
Via Benzinga

Performance

YTD
+170.58%
+170.58%
1 Month
+11.65%
+11.65%
3 Month
-5.49%
-5.49%
6 Month
+157.28%
+157.28%
1 Year
+70.34%
+70.34%

More News

Read More
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
Could This Be the Catalyst Novavax Needs to Get Its Stock Rallying Again?
Via The Motley Fool
Exposures COVID-19
How Is The Market Feeling About Novavax?
Via Benzinga
Looking Into Novavax's Recent Short Interest
Via Benzinga
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
Via FinancialNewsMedia
Exposures COVID-19
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
FDA Approves Novavax's Updated COVID Vaccine Targeting Currently Circulating Variants
Via Benzinga
Exposures COVID-19 Product Safety
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
From FN Media Group LLC
Via GlobeNewswire
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy?
Via The Motley Fool
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
Via Benzinga
Exposures COVID-19 Product Safety
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
Via Investor's Business Daily
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
Via Benzinga
Topics ETFs
Exposures COVID-19 Product Safety
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Via MarketBeat
Exposures COVID-19 Product Safety
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
Via MarketBeat
Exposures COVID-19
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
Via Benzinga
Exposures COVID-19
NVAX Stock Earnings: Novavax Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Wall Street's Top 10 Stock Calls This Week - Saturday, Aug. 3
Via Talk Markets
Where Will Novavax Be in 5 Years?
Via The Motley Fool
What's Going On With Novavax (NVAX) Stock?
Via Benzinga
Moderna Slashes Its Outlook On 'Very Low' European Sales Despite Quarterly Beat
Via Investor's Business Daily
JPMorgan Just Cut Its Price Target on These 3 Stocks: July 31, 2024
Via InvestorPlace
JPMorgan Just Issued a Warning on Novavax (NVAX) Stock
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.